Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Solvency Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
The analysis of the financial ratios over the observed periods reveals several notable trends in the company's operational efficiency and liquidity management.
- Inventory Turnover
- The inventory turnover ratio exhibits a fluctuating pattern, with a peak around early 2019 reaching up to approximately 2.66 times, followed by a general decline through 2020 and 2021, falling as low as 1.44. A slight recovery is noticed in early 2022 but remains below previous highs. This suggests a decrease in the efficiency of inventory management and potentially slower inventory movement in recent periods.
- Receivables Turnover
- The receivables turnover ratio remains relatively stable throughout the timeline, predominantly fluctuating between 5.2 and 6.05 times. Minor variations indicate consistent credit policies and stable collection effectiveness over the quarters, with no significant improvement or deterioration.
- Payables Turnover
- Payables turnover shows increased volatility, with values ranging from around 3.58 to 6.18 times. Notably, periods with lower payables turnover correspond to longer payment periods, indicating flexibility or delays in payable settlements during certain quarters, particularly in late 2019 and parts of 2021.
- Working Capital Turnover
- This ratio demonstrates considerable fluctuation, peaking notably in late 2019 at 3.44 before decreasing markedly in subsequent quarters, reaching a low around 1.42 in late 2022. The decline suggests reduced efficiency in utilizing working capital to generate sales or operational outcomes in recent periods compared to earlier years.
- Average Inventory Processing Period
- There is a clear trend of increasing inventory days from early 2020 onward, rising from approximately 173 days to a peak above 254 days in late 2021, before a modest reduction in early 2022. The prolonged inventory holding period indicates slower stock turnover and potential overstocking or demand challenges.
- Average Receivable Collection Period
- The average collection period remains fairly consistent, typically around 65 to 70 days, with minor quarterly fluctuations. This stability aligns with the steady receivables turnover ratio and suggests steady credit management practices over time.
- Operating Cycle
- The operating cycle shows an initial improvement with decreasing days through 2018 and early 2019, then extends notably from 2020 onwards, increasing from about 239 days to over 320 days in late 2021 before slightly declining. The extension reflects longer durations for inventory processing and receivable collection combined, potentially impacting overall operational efficiency.
- Average Payables Payment Period
- The payment period extends significantly at times, with spikes reaching over 100 days in some quarters of 2021 and around 99 days in late 2019. Conversely, earlier periods and some in 2022 show shorter payables periods closer to 60 days. This variability suggests differing payment strategies or cash management adjustments aligned with operational or market conditions.
- Cash Conversion Cycle
- The cash conversion cycle indicates considerable volatility, decreasing to a low near 111 days in late 2019, which suggests efficient management of cash flows at that time. However, it increases substantially thereafter, peaking above 244 days in late 2021 before dropping back somewhat but remaining elevated near 222 days in late 2022. This longer cycle highlights increased cash tied up in inventory and receivables relative to payables, potentially straining liquidity.
Overall, the data portrays a period of declining operational efficiency in inventory and working capital management after 2019, accompanied by a longer cash conversion cycle. Receivables management remains stable, while payables turnover varies, indicating fluctuating payment terms. The extended inventory holding and operating cycles suggest challenges in inventory movement and cash flow optimization in recent years.
Turnover Ratios
Average No. Days
Inventory Turnover
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | |||||||||||||||||||||||||
| Inventory | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Inventory turnover
= (Cost of sales, excluding amortization and impairment of acquired intangible assetsQ3 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ2 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ1 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ4 2021)
÷ Inventory
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several key trends over the periods analyzed, particularly in cost of sales, inventory levels, and inventory turnover ratio.
- Cost of Sales, Excluding Amortization and Impairment
-
The cost of sales exhibits fluctuations across the quarters. From early 2018 through the end of that year, figures ranged mostly between approximately 421 million and 488 million US dollars, with a notable peak in March 2019 reaching over 600 million. Subsequently, the cost peaked sharply in December 2021 at around 660 million and further escalated to a high near 754 million in the first half of 2022, before declining moderately towards the third quarter of 2022 to roughly 470 million. This pattern indicates some volatility and increased expenses in late 2021 and early 2022 periods.
- Inventory Levels
-
Inventory values show a general upward trend throughout the observed periods. Starting at just below 900 million US dollars in early 2018, inventory progressively increased, reaching levels above 1.35 billion by late 2021, before a slight decrease and renewed upward move again in 2022 to approximately 1.37 billion by September. This consistent growth suggests accumulation of stock or buildup of raw materials and finished goods over time.
- Inventory Turnover Ratio
-
The inventory turnover ratio exhibits a declining trend after peaking in the first half of 2019 at about 2.66 times. Beginning with values near 1.9 in early 2018, it briefly rose above 2.5 in early to mid-2019, indicating increased efficiency in managing inventory relative to sales. However, from late 2019 onward, the ratio steadily decreased, reaching a low near 1.44 in the last quarter of 2021, followed by a mild recovery to values close to 1.7 to 2.0 through 2022. A declining turnover ratio signals a slower rate of inventory movement relative to sales, which may suggest overstocking or slower sales velocity in some periods.
Overall, the data indicates rising inventory levels accompanied by fluctuating cost of sales and a declining trend in inventory turnover ratio after 2019. The increased cost of sales in late 2021 and early 2022 alongside high inventory levels and reduced turnover efficiency may warrant deeper investigation into sales performance, supply chain dynamics, or demand fluctuations during these periods.
Receivables Turnover
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Product, net | |||||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Receivables turnover
= (Product, netQ3 2022
+ Product, netQ2 2022
+ Product, netQ1 2022
+ Product, netQ4 2021)
÷ Accounts receivable, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net product revenue demonstrates a fluctuating trend over the observed quarters. Starting at approximately $2.52 billion in the first quarter of 2018, it generally increased through 2018, peaking around $2.92 billion by the end of 2019. Following this peak, the revenue experienced a decline, particularly notable in 2020 with a steep drop to about $2.3 billion by the year's end, and continued a downward trajectory through 2022, reaching roughly $1.96 billion by the third quarter of 2022.
Accounts receivable, net, shows a somewhat variable pattern with values ranging between roughly $1.54 billion and $2.14 billion. There is an initial increase from early 2018, peaking mid-2020, then a general decline through subsequent periods. The lowest accounts receivable are observed in late 2021 and into 2022, suggesting potential tightening in credit or collection practices or decreased sales volume.
The receivables turnover ratio mostly oscillates between 5.2 and 6.05 times throughout the periods. The ratio saw a modest increase from early 2018 through late 2019, indicating improved efficiency in collecting receivables during this phase. However, after a small dip during 2020, the turnover stabilized around 5.2 to 5.7 times through 2021 and into 2022, suggesting consistent collection efficiency despite fluctuations in sales and receivables balances.
- Overall Analysis
- The financial data indicate that while the company experienced strong net product revenues up to 2019, the subsequent years have seen a marked decrease. This decline may affect cash flow and working capital management.
- The pattern in accounts receivable correlates broadly with revenues, peaking in mid-2020 and then decreasing thereafter, which could reflect changes in sales volume or credit policies.
- The receivables turnover ratio reflects mild variability but remains relatively stable, indicating that collection processes have not deteriorated significantly even during periods of revenue decline.
- These trends suggest the company faces challenges in revenue generation but maintains steady receivables management efficiency.
Payables Turnover
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | |||||||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Payables turnover
= (Cost of sales, excluding amortization and impairment of acquired intangible assetsQ3 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ2 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ1 2022
+ Cost of sales, excluding amortization and impairment of acquired intangible assetsQ4 2021)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals notable fluctuations in key operational metrics over the observed periods. The cost of sales, excluding amortization and impairment of acquired intangible assets, exhibits a generally increasing trend from the beginning of 2018 to the end of 2021, with some intermittent declines. Early in the period, costs hovered between approximately 420,000 and 490,000 thousand US dollars, but by the end of 2021, costs had risen substantially, peaking around 660,100 thousand US dollars. However, there is a sharp decrease towards the third quarter of 2022, where costs decline to roughly 469,500 thousand US dollars, indicating a reduction in spending or improved cost management during the most recent quarters.
Accounts payable demonstrate variable behavior without a consistent upward or downward trajectory. Initially, balances ranged between approximately 295,700 and 530,800 thousand US dollars, with a significant increase observed particularly in late 2019 and early 2021, where values surpassed 500,000 thousand US dollars. These peaks suggest periods of deferred payment obligations or increased procurement. Following these spikes, accounts payable decrease again in 2022, falling to the mid-300,000 to 400,000 thousand range, aligning with the downward trend in cost of sales observed in the same period.
The payables turnover ratio, which reflects the frequency of paying accounts payable during each period, fluctuates considerably across the quarters. Early ratios fluctuate between 4.89 and 5.91, indicative of relatively efficient payment cycles. However, the ratio dips to its lowest points around 3.58 and 3.68 during late 2019 and late 2021, suggesting slower payment cycles or an accumulation of payables during those periods. Conversely, spikes in the turnover ratio are observed in the later quarters of 2022, reaching values above 5.5 and peaking at 6.18, implying a faster rate of settling payables towards the most recent data points.
Overall, the trends suggest a phase of rising costs and increased payment obligations through much of the 2018-2021 timeframe, followed by signs of cost containment and improved accounts payable turnover in 2022. The volatile payables turnover ratio reflects changing cash flow management strategies or altered credit terms with suppliers. The recent reduction in cost of sales alongside more rapid payment cycles may indicate an enhanced focus on operational efficiency and liquidity management in the current operating environment.
Working Capital Turnover
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||||||
| Working capital | |||||||||||||||||||||||||
| Product, net | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Working capital turnover
= (Product, netQ3 2022
+ Product, netQ2 2022
+ Product, netQ1 2022
+ Product, netQ4 2021)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data indicates distinct patterns in working capital, product net sales, and working capital turnover over the analyzed periods. The following summarizes the observed trends and insights.
- Working Capital Trends
- Working capital experienced fluctuations throughout the periods, beginning at approximately 7.04 billion USD at the end of March 2018 and reaching a low near 3.15 billion USD by December 2020. Following this low point, working capital showed a recovery trend, increasing steadily to approximately 5.84 billion USD by September 2022. This suggests periodic tightening and subsequent loosening of short-term liquidity resources over the years.
- Product Net Sales Trends
- Product net sales displayed a generally declining trend across the time span. Sales started at around 2.52 billion USD in March 2018, with minor fluctuations initially, but by December 2020, sales had decreased to approximately 2.30 billion USD. The decline persisted slightly, with net sales reaching roughly 1.96 billion USD by September 2022. This downward trend indicates a reduction in product revenue, which may reflect market challenges, competition, or other business factors affecting sales volumes or pricing.
- Working Capital Turnover Ratios
- The working capital turnover ratio demonstrated variability inversely related in some periods to the fluctuations in working capital. Starting at 1.49 in March 2018, the ratio increased significantly, peaking at 3.44 in March 2020, indicating more efficient use of working capital earlier on. However, post-March 2020, the ratio exhibited a declining trend, falling to 1.42 by September 2022. This decline suggests decreased efficiency in utilizing working capital to generate product sales in the later periods observed.
- Integrated Observations
- Periods with lower working capital corresponded often with higher turnover ratios, reflecting more effective working capital use. Conversely, the rise in working capital from late 2020 onwards coincided with a decreasing turnover ratio, which may imply accumulating working capital without proportional increases in product sales. The sustained decline in product net sales alongside reduced turnover ratios highlights potential operational or market pressures affecting revenue generation and asset utilization efficiency.
Average Inventory Processing Period
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of the inventory turnover and average inventory processing period over the observed time frame reveals notable fluctuations and trends in inventory management efficiency.
- Inventory Turnover Ratio
- This ratio experienced an initial gradual increase from 1.9 in March 2018 to a peak of 2.66 in September 2019, indicating improved efficiency in managing and selling inventory during this period. Following the peak, a decline is observed throughout 2020, reaching a low of 1.44 in September 2021, which suggests a deceleration in inventory turnover and potential challenges in inventory movement. The ratio shows signs of recovery at the end of 2021 and into 2022, rising back up to 1.96 by March 2022, although it remains below the peak levels observed in 2019.
- Average Inventory Processing Period (Days)
- This metric inversely mirrors inventory turnover trends. Initially, the processing period decreases from 192 days in March 2018 to 137 days in September 2019, aligning with the increased turnover ratio and reflecting faster inventory cycles. However, from late 2019 onward, the processing period increases significantly, peaking at 254 days in September 2021, indicating a slowdown in inventory movement and possible overstocking or reduced sales velocity. In early 2022, the processing period decreases again to 186 days by June but rises back to 212 days in September 2022, suggesting ongoing volatility and fluctuating inventory management effectiveness.
- Overall Insights
- The data indicates a phase of improved inventory management efficiency up to late 2019, followed by a period of deterioration likely influenced by external or internal factors affecting sales and supply chain dynamics. The partial recovery in turnover rates alongside reduced processing periods in early 2022 points to some restoration of operational effectiveness, although remaining below previous optimal levels. The fluctuations highlight the need for continued focus on inventory control strategies to maintain balanced turnover and processing periods.
Average Receivable Collection Period
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of the receivables turnover ratio over the examined quarters reveals a relatively stable yet mildly fluctuating pattern. Starting at 5.41 in March 2018, the ratio exhibits gradual improvements, peaking at 6.05 by December 2019. This upward trend suggests enhanced efficiency in collecting receivables during this period. However, post-December 2019, the turnover ratio experiences a slight decline and fluctuates around the 5.2 to 5.7 range through September 2022, indicating some volatility but no marked deterioration in collection efficiency.
Concurrently, the average receivable collection period, expressed in days, exhibits an inverse relationship to the turnover ratio, as anticipated. Initially, the collection period remains relatively consistent around 66 to 68 days from March 2018 through early 2019. Notably, there is a decline to 60 days by December 2019, corresponding with the peak in receivables turnover, reflecting faster collections. Following this, the collection period lengthens and fluctuates between 64 and 70 days, demonstrating a moderate increase in the time taken to collect receivables in recent quarters.
Overall, while the company maintained relatively effective receivables management up to the end of 2019, there is evidence of slight weakening thereafter with increased collection days and a marginal decline in turnover. The recent ratios suggest a return to levels similar to those observed in early 2018, indicating that while efficiency has not significantly deteriorated, improvement opportunities exist to optimize receivables collection processes.
- Receivables Turnover Ratio
- Trend of gradual increase from 5.41 to 6.05 until end of 2019, followed by stabilization with minor fluctuations within 5.2 – 5.7 range.
- Average Receivable Collection Period
- Consistent around 66-68 days early on, improvement to 60 days at end of 2019, then increase and variability between 64 and 70 days thereafter.
- Implications
- Collection efficiency peaked before 2020; recent periods show a slight reversal with prolonged collection times and modest declines in turnover.
Operating Cycle
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The analysis of the company's working capital efficiency over the observed periods reveals several key trends in inventory management, receivables collection, and overall operating cycle performance.
- Inventory Processing Period
- The average inventory processing period exhibited considerable fluctuations. Starting at 192 days in early 2018, it generally decreased to a low of 137 days by the third quarter of 2019, indicating improved inventory turnover and potentially better inventory management practices during that time. However, from late 2019 onwards, there was a noticeable upward trend, with the period increasing significantly to reach up to 254 days by the third quarter of 2021. After this peak, a reduction followed in 2022, yet values remained elevated above the earlier years, ending at 212 days. This pattern suggests challenges in inventory processing or demand variability affecting inventory levels in the latter periods.
- Receivable Collection Period
- The average receivable collection period remained relatively stable throughout the period under review, oscillating narrowly between 60 and 70 days. This consistency indicates steadiness in the company's credit policy enforcement and customer payment behavior. Minor fluctuations do not signify significant changes to the collection process, maintaining a steady cash conversion framework.
- Operating Cycle
- The operating cycle, a composite measure of inventory turnover plus receivable collection, demonstrates considerable variability mirroring the inventory processing trends. It reduced to a minimum of around 200 days in late 2019, but subsequently increased significantly to peak at 324 days by the fourth quarter of 2021. This increase reflects slower conversion of resources into cash, likely driven by elevated inventory durations despite stable receivables. In 2022, there was a downward adjustment in the operating cycle, yet it remained longer than the earlier years, ending near 281 days.
In summary, while the company's receivable collection efficiency remained stable over the years, the inventory processing dynamics substantially influenced the operating cycle. The initial improvement in inventory management up to 2019 was followed by a prolonged period of increased inventory levels or slower turnover, impacting the overall liquidity cycle adversely in the subsequent years. Monitoring and addressing the causes behind rising inventory processing times will be critical to optimizing working capital management going forward.
Average Payables Payment Period
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly payables turnover and average payables payment period reveals notable fluctuations over the observed periods. The payables turnover ratio, which indicates how many times the company pays off its accounts payable during a period, exhibits a generally cyclic pattern with periods of increase followed by declines. Initially, the ratio rises from 4.89 to a peak of 5.91 and then dips subsequently, with the lowest point reaching 3.58 in December 2021. Post that trough, there is a recovery trend as the ratio attains its highest observed value of 6.18 by September 2022. This pattern suggests variability in the company's payment efficiency and supplier relationship management over time.
Correspondingly, the average payables payment period, indicative of the average number of days the company takes to settle its payables, mirrors the inverse trend of the payables turnover. Periods of high turnover ratio correspond with shorter payment periods, and vice versa. Noteworthy is the spike in payment period to 102 days in December 2021, coinciding with the lowest payables turnover ratio, reflecting a delay in payment cycles during this time frame. Conversely, shorter payment periods are observed towards the end of the dataset, dropping to 59 days by September 2022, which aligns with the highest turnover ratio and suggests improved payment promptness.
- Payables Turnover Trend
- Fluctuating between approximately 3.58 and 6.18, indicating variability in payment frequency to suppliers with periods of both acceleration and deceleration.
- Average Payables Payment Period Trend
- Varies between 59 and 102 days, showing inverse movement relative to turnover ratio; longer payment periods correspond with lower turnover values.
- Interpretation
- The inverse correlation suggests that when the company delays payments (longer payment periods), it reduces payables turnover, potentially impacting supplier relations. Recent trends show improved payment timeliness.
Overall, the data indicate periods of both conservative and aggressive payment strategies. The recent increase in payables turnover and corresponding reduction in payment days suggest a shift towards faster settlement of obligations, which might reflect stronger liquidity management or strategic supplier engagement.
Cash Conversion Cycle
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2022 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data points to several noteworthy trends in the operational efficiency and working capital management over the observed periods.
- Average Inventory Processing Period
- This metric exhibits considerable fluctuation between 2018 and 2022. Initially, the days hovered around the 180-190 range throughout 2018, followed by a marked reduction in the first three quarters of 2019, reaching a low near 137 days. Subsequently, there is a notable and steady increase throughout 2020 and 2021, peaking at 254 days in September 2021. In early 2022, the days decrease again but remain elevated relative to the earlier years, ending near 212 days. The trend suggests periods of both improved and deteriorated inventory management efficiency, with an overall increase in inventory holding duration towards the latter part of the timeline.
- Average Receivable Collection Period
- The receivable collection period remains relatively stable over the entire period, generally fluctuating narrowly between 60 and 70 days. Minor variations occur quarter-to-quarter without a definitive upward or downward trend, indicating consistent credit and collection policies and stable customer payment behavior.
- Average Payables Payment Period
- Payment to suppliers displays significant volatility. Starting at around 75 days in early 2018, the period decreases initially but then spikes notably to over 99 days by the end of 2019. This longer payment period suggests a strategy to extend payables, possibly to conserve cash. However, this is followed by a reduction and variability in 2020 and 2021, with another peak exceeding 102 days at the end of 2021. In 2022, the payment period contracts significantly again, reaching lows near 59 days. This cyclical pattern reflects changing supplier payment terms or cash management strategies.
- Cash Conversion Cycle
- The cash conversion cycle follows a pattern closely influenced by the inventory and payables periods. It remains in the 179-200 day range during 2018, then declines steadily through 2019 to reach a low near 111 days. However, there is a reversal in 2020 and 2021 where the cycle lengthens notably, peaking at 244 days in late 2021. Early 2022 sees some improvement with a reduction to approximately 193 days, but still elevated relative to earlier years. This metric highlights periods of improved working capital efficiency followed by phases of extended investment in operations before settling at a higher level than initially observed.
In summary, there is evidence of operational adjustments affecting inventory management and supplier payments that collectively influence the cash cycle dynamics. The receivable collection period remains stable, but fluctuations in inventory processing and payables periods drive the overall working capital efficiency, suggesting strategic shifts in managing liquidity and operational demands across the business cycles examined.